IONTAS is a biotechnology company focussed on the development of novel antibody therapeutics using phage display and proprietary technology platforms. Established in 2014 by John McCafferty (the discoverer of phage display), IONTAS has established partnerships with biotechnology and pharmaceutical companies across the globe. Iontas employs proven expertise in all key areas of therapeutic antibody discovery and development to successfully deliver antibodies to agreed affinities and specificities. Iontas also continues to develop novel platforms for the discovery of antibodies and is proud of a long and prestigious record of peer reviewed publications by its scientific founders and staff. In particular, new platforms are under development for generating antibodies against difficult targets and technologies are under development to improve "manufacturability" as part of the antibody selection criteria. IONTAS and FairJourney Biologics combined capabilities in 2020 as a fee for service antibody discovery company. The combined operations allow a complete offering around antibody discovery. Using fully validated naïve libraries with parallel immune approaches and the unrivalled mammalian display technology to optimise antibody discovery research. The team of more than 100 scientists, anchored in a high-profile network of advisors, has successfully completed more than 150 projects, with over 50 biotechnology and pharmaceutical companies.